PMID- 33304318
OWN - NLM
STAT- MEDLINE
DCOM- 20210521
LR  - 20210521
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication.
PG  - 568861
LID - 10.3389/fendo.2020.568861 [doi]
LID - 568861
AB  - Diabetic mellitus (DM) is a significant public health concern worldwide with an 
      increased incidence of morbidity and mortality, which is particularly due to the 
      diabetic vascular complications. Several pivotal underlying mechanisms are 
      associated with vascular complications, including hyperglycemia, mitochondrial 
      dysfunction, inflammation, and most importantly, oxidative stress. Oxidative 
      stress triggers defective angiogenesis, activates pro-inflammatory pathways and 
      causes long-lasting epigenetic changes to facilitate the development of vascular 
      complications. Therefore, therapeutic interventions targeting oxidative stress 
      are promising to manage diabetic vascular complications. Sirtuin1 (SIRT1), a 
      class III histone deacetylase belonging to the sirtuin family, plays critical 
      roles in regulating metabolism and ageing-related pathological conditions, such 
      as vascular diseases. Growing evidence has indicated that SIRT1 acts as a sensing 
      regulator in response to oxidative stress and attenuates vascular dysfunction via 
      cooperating with adenosine-monophosphate-activated protein kinase (AMPK) to 
      activate antioxidant signals through various downstream effectors, including 
      peroxisome proliferator-activated receptor-gamma co-activator 1 (PGC-1alpha), 
      forkhead transcription factors (FOXOs), and peroxisome proliferative-activated 
      receptor alpha (PPARalpha). In addition, SIRT1 interacts with hydrogen sulfide (H2S), 
      regulates NADPH oxidase, endothelial NO synthase, and mechanistic target of 
      rapamycin (mTOR) to suppress oxidative stress. Furthermore, mRNA expression of 
      sirt1 is affected by microRNAs in DM. In the current review, we summarize recent 
      advances illustrating the importance of SIRT1 in antagonizing oxidative stress. 
      We also discuss whether modulation of SIRT1 can serve as a therapeutic strategy 
      to treat diabetic vascular complications.
CI  - Copyright (c) 2020 Meng, Qin and Liu.
FAU - Meng, Teng
AU  - Meng T
AD  - Shenzhen Key Laboratory for Systemic Aging and Intervention, National Engineering 
      Research Center for Biotechnology (Shenzhen), Medical Research Center, Shenzhen 
      University Health Science Center, Shenzhen, China.
AD  - Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and 
      Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, 
      Shenzhen, China.
AD  - Guangdong Key Laboratory of Genome Stability and Human Disease Prevention, 
      Department of Biochemistry & Molecular Biology, School of Basic Medical Sciences, 
      Shenzhen University, Shenzhen, China.
FAU - Qin, Weifeng
AU  - Qin W
AD  - Shenzhen Key Laboratory for Systemic Aging and Intervention, National Engineering 
      Research Center for Biotechnology (Shenzhen), Medical Research Center, Shenzhen 
      University Health Science Center, Shenzhen, China.
AD  - Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and 
      Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, 
      Shenzhen, China.
FAU - Liu, Baohua
AU  - Liu B
AD  - Shenzhen Key Laboratory for Systemic Aging and Intervention, National Engineering 
      Research Center for Biotechnology (Shenzhen), Medical Research Center, Shenzhen 
      University Health Science Center, Shenzhen, China.
AD  - Key Laboratory of Optoelectronic Devices and Systems of Ministry of Education and 
      Guangdong Province, College of Optoelectronic Engineering, Shenzhen University, 
      Shenzhen, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201116
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.5.1.- (SIRT1 protein, human)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus/drug therapy/*metabolism/pathology
MH  - Diabetic Angiopathies/drug therapy/*metabolism/pathology
MH  - Humans
MH  - Hypoglycemic Agents/metabolism/therapeutic use
MH  - Oxidative Stress/*physiology
MH  - Sirtuin 1/*metabolism
PMC - PMC7701141
OTO - NOTNLM
OT  - SIRT1
OT  - adenosine-monophosphate-activated protein kinase
OT  - diabetic vascular complications
OT  - mechanistic target of rapamycin
OT  - microRNAs
OT  - oxidative stress
EDAT- 2020/12/12 06:00
MHDA- 2021/05/22 06:00
PMCR- 2020/01/01
CRDT- 2020/12/11 06:02
PHST- 2020/06/11 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/12/11 06:02 [entrez]
PHST- 2020/12/12 06:00 [pubmed]
PHST- 2021/05/22 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2020.568861 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Nov 16;11:568861. doi: 
      10.3389/fendo.2020.568861. eCollection 2020.